Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...
AVAC, Health GAP, Knowledge Ecology International (KEI), and Treatment Action Group (TAG) strongly condemn the Trump Administration’s decision to halt funding to the World Health Organization (WHO) in the midst of the urgent COVID-19 global health crisis.
Treatment Action Group (TAG) celebrates publication of the General Comment on “the human right of everyone to participate in and to enjoy the benefits of scientific progress and its applications” (the right to science), and calls the attention of grassroots activists and global civil society working on health to this landmark document.
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).
Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of…
We hope you’re staying safe and sanitized during this difficult time! Here at TAG, we’re fortunate to be able to safely work from home, and advance the fight against HIV, tuberculosis, and hepatitis C — and now against COVID-19.
A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.
The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.
October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…